基于pyrotinib的治疗方法治疗HER2阳性乳腺癌:现在是时候了
Xiaowei Qi1, Qiyun Shi1,2, Juncheng Xuhong1,3
1Department of Breast and Thyroid Surgery, Southwest Hospital, Army Medical University, Chongqing, 400038, China.
Breast cancer research : BCR
|October 3, 2023
概括
作为一种不可逆转的氨酸激酶抑制剂 (TKI),Pyrotinib在治疗HER2阳性乳腺癌 (BC) 中显示出临床有效性. 本综述详细介绍了在转移和新辅助环境中针对HER2阳性BC的基于pyrotinib的治疗方法.
科学领域:
- 在瘤学瘤学.
- 药理学 药理学是指药理学的学科.
- 医学科学 医学科学 医学科学
背景情况:
- 人体表皮生长因子受体2 (HER2) 阳性乳腺癌 (BC) 是一种具有不良预后的侵袭性亚型.
- 针对HER2的疗法,包括单克隆抗体,氨酸激酶抑制剂 (TKI) 和抗体-药物联合体,改善了患者的治疗结果.
- 小分子TKIs提供优势,如口服,更好的血脑屏障透脑转移,和心脏毒性降低与单克隆抗体相比.
研究的目的:
- 审查基于pyrotinib的治疗方法的开发和临床应用.
- 突出皮洛替尼在治疗各种临床环境中的HER2阳性乳腺癌 (BC) 中的作用.
主要方法:
- 对pyrotinib的临床研究和文献的审查.
- 对HER2-阳性BC的转移和新辅助环境中pyrotinib的疗效的分析.
- 与其他针对HER2的治疗方法进行比较,比较pyrotinib的特性.
主要成果:
- 作为一个不可逆转的泛ErbB受体TKI,Pyrotinib已经证明了临床有效性.
- 皮罗替尼在转移性和新辅助性治疗HER2-阳性BC.中显示出前景.
- 皮洛替尼在口服和管理大脑转移方面提供了潜在的优势.
结论:
- 皮罗替尼在治疗HER2阳性乳腺癌方面取得了重大进展.
- 基于pyrotinib的疗法是HER2-阳性BC患者,特别是脑转移患者的有价值的选择.
- 需要进一步研究和临床应用pyrotinib,以优化其在乳腺癌管理中的使用.
更多相关视频
08:59Looking for Driver Pathways of Acquired Resistance to Targeted Therapy: Drug Resistant Subclone Generation and Sensitivity Restoring by Gene Knock-down
Published on: December 11, 2017
7.2K
10:27Testing Targeted Therapies in Cancer using Structural DNA Alteration Analysis and Patient-Derived Xenografts
Published on: July 25, 2020
7.3K
相关概念视频
02:57Targeted Cancer Therapies
7.7K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
There are several types of targeted therapies against...
7.7K
02:50Combination Therapies and Personalized Medicine
4.9K
Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
4.9K
01:26Treatment for Pulmonary Arterial Hypertension: Receptor Tyrosine Kinase Inhibitors and Calcium Channel Blockers
190
Receptor tyrosine kinase inhibitors (TKIs) and calcium channel blockers (CCBs) are two critical categories of drugs employed in the treatment of pulmonary artery hypertension (PAH). PAH is a disease that causes high blood pressure in the pulmonary arteries, resulting in chest pain, fatigue, and shortness of breath.
TKIs, such as imatinib (Gleevec), are particularly effective in tackling the growth and mitogenic factors that become upregulated in PAH patients. These factors contribute to the...
TKIs, such as imatinib (Gleevec), are particularly effective in tackling the growth and mitogenic factors that become upregulated in PAH patients. These factors contribute to the...
190
02:38Mitogens and the Cell Cycle
6.5K
Mitogens and their receptors play a crucial role in controlling the progression of the cell cycle. However, the loss of mitogenic control over cell division leads to tumor formation. Therefore, mitogens and mitogen receptors play an important role in cancer research. For instance, the epidermal growth factor (EGF) - a type of mitogen and its transmembrane receptor (EGFR), decides the fate of the cell's proliferation. When EGF binds to EGFR, a member of the ErbB family of tyrosine kinase...
6.5K
02:49Cancer Therapies
7.7K
Cancer therapies are various modes of treatment, such as surgery, radiation therapy, and chemotherapy that are administered to cancer patients.
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
7.7K
01:23Treatment for Pulmonary Arterial Hypertension: Prostacyclin Receptor Agonists
203
Prostacyclin receptor agonists are a class of therapeutic agents integral to managing pulmonary arterial hypertension (PAH). These drugs operate by mimicking the action of prostaglandin I2, or PGI2, a naturally occurring compound in the body.
These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...
These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...
203